Amneal Pharmaceuticals, Inc.

AMRXNASDAQHealthcare● Active

$13.77

+$0.02(+0.11%)

Market Cap$4.4B

P/E Ratio—

52W High$15.42

52W Low$7.07

Avg Volume1.8M

Open$13.79

Beta1.32

Overview

Amneal Pharmaceuticals, Inc. (AMRX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

AMRX · free cash flow · updated Jun 8, 2026

Core FCF metrics

AMRX · FCF · TTM · margin & CAGR

Free cash flow was $269.9M for FY2025 (fiscal year ending 2025-12-31), up 22.6% year-over-year The FCF margin was 8.9%. Five-year CAGR stands at -3.2%.

FY2025 Free Cash Flow$269.9M▲ +22.6% YoY

Trailing 12M (TTM)$205.3Mtrailing 4 quarters sum

FCF Margin8.9%$269.9M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGR-3.2%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

AMRX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$340.0M(70M)$269.9M▲ +22.6%8.9%

FY2024$295.1M(75M)$220.1M▼ 20.4%7.9%

FY2023$345.6M(69M)$276.4M▲ +1184.1%11.6%

FY2022$65.1M(91M)−$25.5M▼ 113.1%-1.1%

FY2021$241.8M(48M)$194.1M▼ 38.8%9.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

AMRX · P/FCF · FCF yield · FCF per share

Amneal Pharmaceuticals, Inc. (AMRX) trades at a FCF yield of 4.63% and a price-to-free-cash-flow ratio of 20.9x. FCF per share stands at $0.66, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

4.63%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.66

TTM FCF ÷ Shares Outstanding

Price / FCF

x20.9

Share Price ÷ FCF per Share

EV / FCF (TTM)

x33.8

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

AMRX · cash flow statement · operating / investing / financing

For FY2025, Amneal Pharmaceuticals, Inc. generated $340.0M in operating cash flow and spent 70M in capital expenditures, yielding $269.9M in free cash flow.

Operating Activities

+$340.0M

Cash from core business operations

2025-12-31

Investing Activities

−$112.3M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$31.5M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($340.0M) − |CapEx| (70M) = FCF ($269.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

AMRX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Amneal Pharmaceuticals, Inc.YOU

AMRX

$269.9M+22.6%8.9%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Amneal Pharmaceuticals, Inc. (AMRX) reported free cash flow of $269.9M for FY2025 (fiscal year ending 2025-12-31), up 22.6% year-over-year. The FCF margin was 8.9%.

Based on available data, Amneal Pharmaceuticals, Inc. has maintained positive free cash flow for at least 8 fiscal year(s). FCF peaked at $317.2M in FY2020. The 5-year CAGR stands at -3.2%.

Amneal Pharmaceuticals, Inc.'s FCF yield is 4.63% and price-to-FCF ratio is 20.9x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

AMRX free cash flow · 8 questions

Amneal Pharmaceuticals, Inc. free cash flow was $269.9M for FY2025, up 22.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $205.3M.

AMRX free cash flowAMRX FCFAMRX FCF 2025AMRX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Amneal Pharmaceuticals, Inc. · Amneal Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026